Plain Language Summaries
@PlainLangSumm
Followers
273
Following
426
Statuses
681
Updates about the #OpenAccess #PlainLanguageSummaries initiative at Taylor and Francis.
Joined September 2021
Injections are essential in Hospital-at-Home care, but administering them isn’t always simple. This summary explores key challenges faced by patients and providers: #PlainLanguageSummary #HospitalAtHome #PatientCare
0
0
1
The OPTIMIZE trial sheds light on tenapanor’s role in controlling high phosphate in dialysis patients where other treatments fall short. Read more: #PlainLanguageSummary #ChronicKidneyDisease #Nephrology
0
0
0
Sustained phosphate reduction in dialysis patients with tenapanor—18-month study results reveal effectiveness and safety. Read more: #PLSP #KidneyDisease #PhosphateControl
0
0
0
Phase III TORCHLIGHT interim results show toripalimab plus chemotherapy significantly improves progression-free survival in PD-L1-positive metastatic triple-negative breast cancer, with an acceptable safety profile.
0
0
1
This study explores lorlatinib’s role in treating advanced ALK-positive NSCLC in China. Participants showed responses after prior therapies, with three years of data analyzed. Read more: #PlainLanguageSummary #LungCancerAwareness
0
0
0
Optical coherence tomography angiography (OCTA) is advancing diabetic retinopathy assessment, but more research is needed before widespread use. Learn more in this review: #PlainLanguageSummary #MedicalImaging #Ophthalmology
0
1
1
The STRIVE and ReSTORE studies assessed rezafungin as a potential new treatment for candidaemia and invasive candidiasis. Combined findings reveal its promise. Read more: #PLSP #FungalInfections #InfectionControl
0
0
0
Toripalimab, an immunotherapy, shows potential in advanced NSCLC when added to standard chemo. CHOICE-01 study results reveal more: #PlainLanguageSummary #Immunotherapy #LungCancerTreatment
0
0
0
For patients with severe aortic stenosis, transcatheter aortic valve replacement (TAVR) may provide a life-saving alternative to open-heart surgery. Learn how this study evaluated its effectiveness and cost benefits: #PLSP #HeartValveDisease #CardiacCare
0
0
0
Findings from the FRESCO-2 study emphasize the potential of fruquintinib, a therapy reducing blood vessel growth, to improve outcomes in metastatic colorectal cancer. Learn more: #PLSP #ColorectalCancer
0
0
0
Plain language summary of publication #PLSP about the QuANTUM-First trial studying newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukemia #PlainLanguageSummary #Leukemia #FLT3Positive
0
0
0
Could inhaled molgramostim be a new option for autoimmune pulmonary alveolar proteinosis (aPAP) patients? The IMPALA trial assesses its effectiveness in reducing surfactant buildup: #PlainLanguageSummary #Pulmonology #LungDisease
0
0
0
Two studies on SDX/d-MPH (Azstarys®) highlight its effects on growth in children and sleep quality as reported by parents. Discover the findings: #PlainLanguageSummary #ADHD #Neurology
0
0
0
The Migraine Report Card found that 47% of people with frequent migraines and medication use feel high stigma, and 56% report lower quality of life. Stigma was felt most by respondents who were either male, Black, or currently employed #PLSP #Migraines
0
0
0
Managing phosphate levels remains a challenge for dialysis patients. See how the OPTIMIZE trial positions tenapanor as an effective option: #PlainLanguageSummary ChronicKidneyDisease #Nephrology
0
1
1
Insights from the CROWN trial reveal how lorlatinib stacks up against crizotinib for treating ALK-positive NSCLC, focusing on long-term effectiveness and safety outcomes. #PlainLanguageSummary #LungCancer #Oncology #NSCLC #Lorlatinib #Crizotinib
0
0
1
Tenapanor shows promise in managing high phosphate levels in CKD patients on dialysis. Findings from an 18-month study highlight sustained control and safety, learn more here: #PLSP #KidneyDisease #PhosphateControl
0
1
1
Plain Language Summary of Publication #PLSP about how well Larotrectinib works and how safe it is for people with TRK fusion-positive thyroid cancer #PlainLanguageSummary #ThyroidCancer
0
0
0
Phase III TORCHLIGHT interim results show toripalimab plus chemotherapy significantly improves progression-free survival in PD-L1-positive metastatic triple-negative breast cancer, with an acceptable safety profile.
0
0
0
Don’t miss it – we’re pleased to share the first ever interactive Plain Language Summary of Publication (PLSP) article. Click the link and download today! #PlainLanguageSummary #RareDisease
0
3
1